Literature DB >> 35240909

Positioning the new drugs for migraine.

Silvia Benemei1, Enrico Bentivegna2,3, Paolo Martelletti2,3.   

Abstract

Entities:  

Keywords:  CGRP(r) monoclonal antibodies; combination therapy; ditans; drug-drug interactions; gepants; migraine; precision medicine; safety

Mesh：

Substances：

Year:  2022        PMID： 35240909     DOI： 10.1080/17425255.2022.2049236

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN： 1742-5255            Impact factor:   4.481


× No keyword cloud information.
  4 in total

1.  Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine.

Authors:  Fidel Dominique Festin Ambat; Enrico Bentivegna; Paolo Martelletti
Journal:  BioDrugs       Date:  2022-05-16       Impact factor: 7.744

Review 2.  Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain.

Authors:  Adriana Della Pietra; Juha Savinainen; Rashid Giniatullin
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

3.  Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study.

Authors:  Roger Cady; Richard B Lipton; Dawn C Buse; Mette Krog Josiassen; Annika Lindsten; Anders Ettrup
Journal:  J Headache Pain       Date:  2022-07-28       Impact factor: 8.588

4.  Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.

Authors:  Robert P Cowan; Michael J Marmura; Hans-Christoph Diener; Amaal J Starling; Jack Schim; Joe Hirman; Thomas Brevig; Roger Cady
Journal:  J Headache Pain       Date:  2022-09-06       Impact factor: 8.588
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.